Current Report Filing (8-k)
December 17 2021 - 3:07PM
Edgar (US Regulatory)
0001855886
false
0001855886
2021-12-17
2021-12-17
0001855886
arcku:UnitsEachConsistingOfOneShareOfClassCommonStockAndOnethirdOfOneRedeemableWarrantMember
2021-12-17
2021-12-17
0001855886
us-gaap:CommonClassAMember
2021-12-17
2021-12-17
0001855886
arcku:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50Member
2021-12-17
2021-12-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): December 17, 2021
Arbor Rapha Capital Bioholdings Corp. I
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-40967
|
|
82-2427174
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
333 Early Ovington Blvd. Suite 900
Uniondale, NY
|
|
11553
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(516) 506-4200
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Securities
Exchange Act of 1934:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant
|
|
ARCKU
|
|
The Nasdaq Stock Market LLC
|
Class A common stock, par value $0.0001 per share
|
|
ARCK
|
|
The Nasdaq Stock Market LLC
|
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
|
|
ARCKW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).
Emerging growth company
x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Class A common stock
On December 17, 2021, Arbor Rapha Capital Bioholdings
Corp. I (the “Company”) announced that the holders of the Company’s units sold in the Company’s initial public
offering (the “Units”) may elect to separately trade the shares of Class A common stock, par value $0.0001 per share
(“Class A common stock”), and redeemable warrants included in the Units commencing on December 20, 2021. Each Unit
consists of one share of Class A common stock and one-third of one redeemable warrant to purchase one share of Class A common
stock. Any Units not separated will continue to trade on The Nasdaq Stock Market LLC (the “Nasdaq”) under the symbol “ARCKU.”
Any underlying share of Class A common stock and redeemable warrants that are separated will trade on the Nasdaq under the symbols
“ARCK” and “ARCKW,” respectively. No fractional warrants will be issued upon separation of the Units and only
whole warrants will trade. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the
Company’s transfer agent, in order to separate such holders’ Units into shares of Class A common stock and redeemable
warrants.
A copy of the press release issued by the Company announcing
the separate trading of the securities underlying the Units is attached hereto as Exhibit 99.1.
This report may include “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical fact included in this report are forward-looking statements. When used in
this report, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend”
and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements
are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management.
Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed
in the Company’s filings with the Securities and Exchange Commission (the “SEC”). All subsequent written or oral forward-looking
statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements
are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors
section of the Company’s registration statement and prospectus relating to the Company’s initial public offering filed with
the SEC. Copies of such filings are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update
these statements for revisions or changes after the date of this release, except as required by law.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits. The following exhibits are filed with
this Form 8-K:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Arbor Rapha Capital Bioholdings Corp. I
|
|
|
Date: December 17, 2021
|
By:
|
/s/ Ivan Kaufman
|
|
|
Name:
|
Ivan Kaufman
|
|
|
Title:
|
Chief Executive Officer
|
Arbor Rapha Capital Bioh... (NASDAQ:ARCKU)
Historical Stock Chart
From Apr 2024 to May 2024
Arbor Rapha Capital Bioh... (NASDAQ:ARCKU)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Arbor Rapha Capital Bioholdings Corporation I (NASDAQ): 0 recent articles
More Arbor Rapha Capital Bioholdings Corp. I News Articles